SecBot SecBot
8-K ·Filed Jun 25, 2026

TSHA

Taysha Gene Therapies, Inc.
MIXED
Impact 5/10
Horizonweeks Processed4mo ago SEC0001193125-26-282855
8-K material event: Items 1.01
Actionable Insight ◆ Mixed

The substantial dilutive raise at a discount gives the company cash into H2 2028 but weighs on near-term valuation. Watch for the efficacy of TSHA-102 clinical data as the primary catalyst, cash runway is now a non-factor for at least 18 months. The greenshoe exercise in the next 30 days will indicate underwriter demand. Monitor for any corresponding insider lock-up expiration disclosures.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$6.34
T+0 close · Jun 25, 2026 · via day close
Latest settled
−20.50%
T+60 · $5.04
Vs SPY
−26.61%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 26 $6.34entry
  2. T+1 · 5mo ago +6.15%α +4.50% · $6.73
  3. T+5 · 4mo ago +3.00%α +0.83% · $6.53
  4. T+20 · 4mo ago −8.04%α −9.30% · $5.83
  5. T+60 · 8w ago −20.50%α −26.61% · $5.04
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Taysha Gene Therapies priced a $200M underwritten public offering of 32,500,001 common shares at $6.00/share and 833,333 pre-funded warrants at $5.999/warrant, alongside a 30-day underwriter option for up to 5,000,000 additional shares. The offering, closed simultaneously with this 8-K, was executed at a 13.5% discount to the prior day's close of $6.94, raising ~$187.4M in net proceeds (or ~$215.6M if the greenshoe is fully exercised). The company states these funds extend its cash runway into H2 2028. The dilutive transaction offsets the capital-extending benefit, making the net effect neutral with a modest negative bias from the discount.

Key Financial Metrics

Deal Value
$200.0M

Key Facts

  • Priced 32,500,001 common shares at $6.00/share and 833,333 pre-funded warrants at $5.999/warrant
  • Public offering price of $6.00 represents a ~13.5% discount to prior close of $6.94
  • Gross proceeds of ~$200.0M; estimated net proceeds of ~$187.4M (or ~$215.6M if greenshoe fully exercised)
  • Underwriters granted 30-day option to purchase up to 5,000,000 additional shares
  • Closing expected June 26, 2026; proceeds to fund operations into H2 2028
  • Offering issued under existing S-3ASR shelf registration (File No. 333-291244), filed Nov 4, 2025
  • Pre-funded warrants have a $0.001 exercise price and are exercisable immediately until exercised in full

Financial Impact

The company raised ~$187.4M net from the offering. Based on 32.5M new shares issued versus prior outstanding (not specified), the dilution is significant, likely 50–100%+ increase in share count for a ~$2.0B market cap biotech. The ~13.5% discount to market is substantial for a non-distressed follow-on.

share_dilutioncash_positioncash_runway

Risk Factors

  • Dilution from the offering is substantial, affecting EPS and per-share valuation even if cash runway is extended
  • At-the-market discount of ~13.5% may signal weak demand or urgency, pressuring the stock near term
  • Clinical-stage biotech with no approved products; reliance on TSHA-102 data for value creation
  • Underwriters' decision on greenshoe option (up to 5M additional shares) will reflect real-time demand

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
95% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 9 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-282855
Document: d121397dex41.htm0001193125-26-282855
Document: d121397d8k.htm0001193125-26-282855
Document: d121397dex51.htm0001193125-26-282855
Document: d121397dex992.htm0001193125-26-282855
Document: d121397dex991.htm0001193125-26-282855
Document: 0001193125-26-282855-index-headers.html0001193125-26-282855
Document: 0001193125-26-282855-index.html0001193125-26-282855
Document: 0001193125-26-282855.txt0001193125-26-282855

Track record

14 reports on TSHA

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +20.50% at T+60 after the Jun 25, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $4.06 Now $4.06 −0.00% settles Feb 16
  2. Nov 12, 20264d ago Press Release Neutral 5/10 Entry $4.21 Now $4.06 −3.56% settles Feb 10
  3. Aug 11, 202613w ago Press Release Neutral 5/10 Entry $6.41 to $4.09 Now $4.06 −36.61% ▼ −36.14% −31.03% vs SPY
  4. Jun 25, 202620w ago 8-K Mixed 5/10 Viewing Entry $6.34 to $5.04 Now $4.06 −35.96% ▼ −20.50% −26.61% vs SPY
  5. Jun 25, 202620w ago 424B5 Bearish 6/10 Entry $6.34 to $5.04 Now $4.06 +35.96% ▲ +20.50% +26.61% vs SPY
  6. Jun 24, 202620w ago Press Release Bearish 7/10 Entry $6.21 to $5.02 Now $4.06 +34.62% ▲ +19.16% +22.89% vs SPY
  7. Jun 5, 202623w ago Press Release Neutral 2/10 Entry $5.50 to $5.69 Now $4.06 −26.18% ▲ +3.45% −0.55% vs SPY
  8. May 6, 202627w ago 8-K Neutral 5/10 No price data
  9. May 6, 202627w ago Press Release Mixed 7/10 Entry $6.98 to $5.86 Now $4.06 −41.83% ▼ −16.05% −18.11% vs SPY
  10. Apr 29, 202628w ago Press Release Neutral 1/10 Entry $6.27 to $5.52 Now $4.06 −35.25% ▼ −11.96% −16.07% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 5h 45m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 25, 2026